Objective: to evaluate the stem cell in treating renal diseases. To evaluate the effect of stem cells on renal cell apoptosis and necroptosis. Background: The use of stem cells is the hope for all patients with end-stage renal diseases. We isolate stem cells from umbilical cord blood to treat renal diseases by using the Vero cell line as a renal cell which is treated by hydrogen peroxide as renal failure. P53, RIPK1, and EGFR genes were detected by RT PCR to show the improvement by using stem cell therapy for renal diseases. Mesenchymal stem cells are the future hope for the treatment of renal diseases associated with renal cell apoptosis and necroptosis.
Methodology: Mesenchymal CD105 Stem Cells Separation from Umbilical Cord Blood from 20 pregnant females. By forming buffy coat mononuclear leukocytes. Magnetic labeling of CD105 and Separation to stem cells. stem cell proliferation by using Dulbecco Modified Eagle medium (DMEM). After proliferation passages 1, 2, and 3 freeze cells at -20c. For one week then thawing at room temperature to make stem cell extraction. Vero cell line treated by H2O2 1.6 mm for 5 hours to reach sub-lethal. The cytotoxicity of the cell was caused by hydrogen peroxide measured by MTT assay and Spectrophotometry. The Vero cell line is divided into 4 groups group1: normal control, group 2:  sub-lethal, group 3: sub-lethal treated by stem cell extraction, and group 4: sub-lethal treated by stem cells. P53, RIPK1, and EGFR genes were detected in 4 groups by RT PCR. Results: P53, RIPK1, and EGFR levels showed a highly significant difference among studied groups with elevated levels of P53 and RIPK1 and reduced levels of EGFR in the sub-lethal renal cell group with an improvement of cells treated with mesenchymal stem cells. Mesenchymal stem cells showed better results when compared with mesenchymal stem cell extract. Conclusion: Mesenchymal stem cells demonstrated a good effect on renal cell line injury, apoptosis, and necroptosis.